trending Market Intelligence /marketintelligence/en/news-insights/trending/d9feksyctz7pjhtxclgzla2 content esgSubNav
In This List

Seres Therapeutics adds former Novartis executive to board

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Seres Therapeutics adds former Novartis executive to board

Cambridge, Mass.-based biotechnology company Seres Therapeutics Inc. appointed Meryl Zausner as a board member.

Zausner previously served as chief financial and administrative officer of Novartis AG unit Novartis Pharmaceuticals Corp. and a member of the U.S. pharmaceutical executive committee and global finance leadership team.

Seres Therapeutics develops medicines using live bacteria to treat diseases resulting from functional deficiencies of microorganisms within the body.